じんま疹の世界市場レポート 2025年

じんま疹市場規模は、今後数年間で急成長が見込まれます。2029年の年間平均成長率（CAGR）は18.0%で92億3,000万米ドルに成長します。予測期間中の成長は、慢性じんま疹症例の増加、生物学的療法の採用拡大、皮膚科研究への投資増加、高度アレルギー診断へのアクセス拡大、個別化医療の開発などの要因に起因すると考えられます。この期間の主な動向としては、AIを活用した診断ツール、新規生物製剤の開発、個別化免疫療法の進展、ウェアラブル皮膚モニタリングデバイス、アレルギー管理における遠隔医療の利用などが挙げられます。

皮膚疾患に対する認識と治療の高まりが、今後数年間のじんま疹市場の成長を牽引すると予想されます。汚染レベルの上昇が皮膚アレルギーや症状の増加に寄与し、より良い認識と高度な治療に対する需要を後押ししています。じんま疹は、免疫系の反応を強調し、研究を促進し、診断法を改善し、標的治療を進歩させることで、皮膚病に対する認識と治療を高める上で重要な役割を果たしています。例えば、2024年2月、米国の非営利団体であるThe Skin Cancer Foundationは、米国人の5人に1人が70歳までに皮膚がんを発症し、米国では1時間に2人以上が死亡していると報告しました。5回以上日焼けをするとメラノーマのリスクが2倍になることから、予防対策が急務であることが強調されています。このように、皮膚疾患に対する意識の高まりと治療が、じんま疹市場の成長を後押ししています。

同市場の主要企業は、肥満細胞の活性化を標的とすることで慢性自然発症じんま疹を管理する肥満細胞阻害抗体などの革新的なソリューションに注力しています。肥満細胞阻害抗体はモノクローナル抗体で、特定の受容体やシグナル伝達経路を阻害することで肥満細胞の活性化や脱顆粒を阻害し、アレルギー反応や炎症、その他の肥満細胞が介在する疾患を抑制します。例えば、2024年5月、米国のバイオテクノロジー企業であるAllakos Inc.は、慢性自然発症じんま疹（CSU）の治療薬であるAK006の第1相臨床試験の開始を発表しました。この革新的な治療薬は、IgE依存性およびIgE非依存性の肥満細胞活性化経路の両方を標的とし、抗ヒスタミン薬やこれまでの生物学的製剤による治療に抵抗性を示す患者において、より高い効果が期待できます。AK006は、Siglec-6受容体を介して肥満細胞の活性を選択的に阻害することで、CSU治療においてより包括的で持続的な解決策を提供することを目指しており、じんま疹治療および免疫療法研究において重要な一歩を踏み出すものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のじんま疹PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のじんま疹市場：成長率分析
• 世界のじんま疹市場の実績：規模と成長、2019年～2024年
• 世界のじんま疹市場の予測：規模と成長、2024年～2029年、2034年
• 世界のじんま疹総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のじんま疹市場：タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 急性じんま疹
• 慢性じんま疹
• 世界のじんま疹市場：薬剤クラス別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 抗ヒスタミン薬
• 抗炎症薬
• 抗うつ薬
• モノクローナル抗体
• その他の薬物クラス
• 世界のじんま疹市場：投与経路別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 経口
• 非経口
• その他の投与経路
• 世界のじんま疹市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界のじんま疹市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界のじんま疹市場、急性じんま疹の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• アレルギーじんま疹
• 感染性じんま疹
• 薬物誘発性じんま疹
• お問い合わせじんま疹
• 世界のじんま疹市場、慢性じんま疹の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 慢性自発性じんま疹（CSU）
• 慢性誘導性じんま疹（CIndU）

第7章 地域別・国別分析

• 世界のじんま疹市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界のじんま疹市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• じんま疹市場：競合情勢
• じんま疹市場：企業プロファイル
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceutical Industries Ltd
• Incyte Corporation
• Kyowa Kirin Co. Ltd.
• Dr. Reddy's Laboratories Ltd
• Cipla Ltd.
• Amneal Pharmaceuticals Inc
• Glenmark Pharmaceuticals Ltd
• Torrent Pharmaceuticals
• Almirall S.A.
• Argenx SE
• BioCryst Pharmaceuticals Inc.
• Pharvaris NV
• Revolution Medicines Inc.
• Allakos

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• じんま疹市場2029年：新たな機会を提供する国
• じんま疹市場2029年：新たな機会を提供するセグメント
• じんま疹市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Urticaria, commonly known as hives, is a skin condition characterized by red, itchy, and raised welts. It results from an allergic reaction, stress, or unknown triggers, leading to the release of histamine. The condition can be acute (lasting less than six weeks) or chronic (persisting for longer periods). Treatment typically includes antihistamines, avoiding triggers, and, in more severe cases, corticosteroids or immunotherapy.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main types of urticaria are acute urticaria and chronic urticaria. Acute urticaria is a sudden-onset condition that lasts less than six weeks, marked by red, itchy, and swollen welts, often triggered by allergic reactions, infections, medications, insect stings, or food allergens. Treatment options include drug classes such as antihistamines, anti-inflammatory medications, antidepressants, monoclonal antibodies, and others, administered through oral, parenteral, or other routes. These treatments are distributed via various channels, including hospital pharmacies, online pharmacies, and retail pharmacies, serving end users such as hospitals, homecare settings, specialty clinics, and others.

The Urticaria market research report is one of a series of new reports from The Business Research Company that provides Urticaria market statistics, including Urticaria industry global market size, regional shares, competitors with a Urticaria market share, detailed Urticaria market segments, market trends and opportunities, and any further data you may need to thrive in the Urticaria industry. This Urticaria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The urticaria market size has grown rapidly in recent years. It will grow from$4.03 billion in 2024 to $4.77 billion in 2025 at a compound annual growth rate (CAGR) of 18.2%. The growth during the historic period can be attributed to factors such as the increasing prevalence of allergies, growing awareness of skin disorders, advancements in immunology and biologics, rising demand for antihistamines, and improvements in diagnostic techniques.

The urticaria market size is expected to see rapid growth in the next few years. It will grow to$9.23 billion in 2029 at a compound annual growth rate (CAGR) of 18.0%. The growth during the forecast period can be attributed to factors such as the rising cases of chronic urticaria, growing adoption of biologic therapies, increasing investments in dermatology research, expanding access to advanced allergy diagnostics, and the development of personalized medicine. Key trends during this period include AI-powered diagnostic tools, the development of novel biologics, advancements in personalized immunotherapy, wearable skin monitoring devices, and the use of telemedicine for allergy management.

The growing awareness and treatment of skin diseases are expected to drive the growth of the urticaria market in the coming years. Rising pollution levels contribute to an increase in skin allergies and conditions, boosting the demand for better awareness and advanced treatments. Urticaria plays a significant role in increasing skin disease awareness and treatment by highlighting immune system responses, promoting research, improving diagnostics, and advancing targeted therapies. For example, in February 2024, The Skin Cancer Foundation, a US-based nonprofit, reported that 1 in 5 Americans will develop skin cancer by age 70, with over 2 deaths occurring every hour in the U.S. This underscores the urgent need for preventive measures, as having five or more sunburns doubles the risk of melanoma. As such, the rising awareness and treatment of skin diseases are propelling the growth of the urticaria market.

Key players in the market are focusing on innovative solutions such as mast cell inhibitor antibodies to manage chronic spontaneous urticaria by targeting mast cell activation. Mast cell inhibitor antibodies are monoclonal antibodies that block the activation or degranulation of mast cells by inhibiting specific receptors or signaling pathways, thereby reducing allergic reactions, inflammation, and other mast cell-mediated disorders. For instance, in May 2024, Allakos Inc., a US-based biotechnology company, announced the initiation of a Phase 1 clinical trial for AK006, a treatment for chronic spontaneous urticaria (CSU). This innovative therapy targets both IgE-dependent and IgE-independent mast cell activation pathways, offering the potential for greater efficacy in patients who are resistant to antihistamines or prior biologic treatments. By selectively inhibiting mast cell activity through the Siglec-6 receptor, AK006 aims to provide a more comprehensive and lasting solution for CSU management, marking a significant step forward in urticaria treatment and immunotherapy research.

In April 2024, Incyte Corporation, a US-based biopharmaceutical company, acquired Escient Pharmaceuticals for $750 million. This acquisition aims to enhance Incyte's portfolio in inflammation and autoimmunity by advancing first-in-class oral Mas-related G protein-coupled receptor X2 (MRGPRX2) and Mas-related G protein-coupled receptor X4 (MRGPRX4) antagonists, which have the potential to improve treatments for chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), atopic dermatitis (AD), cholestatic pruritus, and other inflammatory disorders. Escient Pharmaceuticals, a US-based clinical-stage biotechnology company, focuses on developing small-molecule therapies for chronic urticaria and severe pruritus.

Major players in the urticaria market are Sanofi S.A., Novartis AG, GlaxoSmithKline PLC, Roche Holding AG, Viatris Inc., Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Incyte Corporation, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd, Cipla Ltd., Amneal Pharmaceuticals Inc, Glenmark Pharmaceuticals Ltd, Torrent Pharmaceuticals, Almirall S.A., Argenx SE, BioCryst Pharmaceuticals Inc., Pharvaris NV, Revolution Medicines Inc., and Allakos.

North America was the largest region in the urticaria market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in urticaria report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the urticaria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The urticaria market consists of sales of corticosteroids, biologics, immunosuppressants, leukotriene receptor antagonists, and topical anti-inflammatory creams or gels. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Urticaria Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on urticaria market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for urticaria ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The urticaria market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Acute Urticaria; Chronic Urticaria
• 2) By Drug Class: Antihistamines; Anti-inflammation Medications; Antidepressants; Monoclonal Antibodies; Other Drug Classes
• 3) By Route of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Acute Urticaria: Allergic Urticaria; Infectious Urticaria; Drug-Induced Urticaria; Contact Urticaria
• 2) By Chronic Urticaria: Chronic Spontaneous Urticaria (CSU); Chronic Inducible Urticaria (CIndU)
• Companies Mentioned: Sanofi S.A.; Novartis AG; GlaxoSmithKline PLC; Roche Holding AG; Viatris Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Urticaria Market Characteristics

3. Urticaria Market Trends And Strategies

4. Urticaria Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Urticaria Growth Analysis And Strategic Analysis Framework

• 5.1. Global Urticaria PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Urticaria Market Growth Rate Analysis
• 5.4. Global Urticaria Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Urticaria Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Urticaria Total Addressable Market (TAM)

6. Urticaria Market Segmentation

• 6.1. Global Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Urticaria
• Chronic Urticaria
• 6.2. Global Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antihistamines
• Anti-Inflammation Medications
• Antidepressants
• Monoclonal Antibodies
• Other Drug Classes
• 6.3. Global Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Urticaria Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.5. Global Urticaria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End-Users
• 6.6. Global Urticaria Market, Sub-Segmentation Of Acute Urticaria, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Allergic Urticaria
• Infectious Urticaria
• Drug-Induced Urticaria
• Contact Urticaria
• 6.7. Global Urticaria Market, Sub-Segmentation Of Chronic Urticaria, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Spontaneous Urticaria (CSU)
• Chronic Inducible Urticaria (CIndU)

7. Urticaria Market Regional And Country Analysis

• 7.1. Global Urticaria Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Urticaria Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Urticaria Market

• 8.1. Asia-Pacific Urticaria Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Urticaria Market

• 9.1. China Urticaria Market Overview
• 9.2. China Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Urticaria Market

• 10.1. India Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Urticaria Market

• 11.1. Japan Urticaria Market Overview
• 11.2. Japan Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Urticaria Market

• 12.1. Australia Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Urticaria Market

• 13.1. Indonesia Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Urticaria Market

• 14.1. South Korea Urticaria Market Overview
• 14.2. South Korea Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Urticaria Market

• 15.1. Western Europe Urticaria Market Overview
• 15.2. Western Europe Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Urticaria Market

• 16.1. UK Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Urticaria Market

• 17.1. Germany Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Urticaria Market

• 18.1. France Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Urticaria Market

• 19.1. Italy Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Urticaria Market

• 20.1. Spain Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Urticaria Market

• 21.1. Eastern Europe Urticaria Market Overview
• 21.2. Eastern Europe Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Urticaria Market

• 22.1. Russia Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Urticaria Market

• 23.1. North America Urticaria Market Overview
• 23.2. North America Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Urticaria Market

• 24.1. USA Urticaria Market Overview
• 24.2. USA Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Urticaria Market

• 25.1. Canada Urticaria Market Overview
• 25.2. Canada Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Urticaria Market

• 26.1. South America Urticaria Market Overview
• 26.2. South America Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Urticaria Market

• 27.1. Brazil Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Urticaria Market

• 28.1. Middle East Urticaria Market Overview
• 28.2. Middle East Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Urticaria Market

• 29.1. Africa Urticaria Market Overview
• 29.2. Africa Urticaria Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Urticaria Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Urticaria Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Urticaria Market Competitive Landscape And Company Profiles

• 30.1. Urticaria Market Competitive Landscape
• 30.2. Urticaria Market Company Profiles
  • 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Urticaria Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Ltd
• 31.2. Sun Pharmaceutical Industries Ltd
• 31.3. Incyte Corporation
• 31.4. Kyowa Kirin Co. Ltd.
• 31.5. Dr. Reddy's Laboratories Ltd
• 31.6. Cipla Ltd.
• 31.7. Amneal Pharmaceuticals Inc
• 31.8. Glenmark Pharmaceuticals Ltd
• 31.9. Torrent Pharmaceuticals
• 31.10. Almirall S.A.
• 31.11. Argenx SE
• 31.12. BioCryst Pharmaceuticals Inc.
• 31.13. Pharvaris NV
• 31.14. Revolution Medicines Inc.
• 31.15. Allakos

32. Global Urticaria Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Urticaria Market

34. Recent Developments In The Urticaria Market

35. Urticaria Market High Potential Countries, Segments and Strategies

• 35.1 Urticaria Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Urticaria Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Urticaria Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r35006_Urticaria_GMR_2025